News Releases

Cannabix Technologies Applauds Canadian Task Force Report on Cannabis Legalization and its Focus on Marijuana Impaired Driving

December 14, 2016

Vancouver, British Columbia, December 14, 2016 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”)  After a preliminary review of the findings of the Canadian special task force released on December 13, 2016, on the future regulation of recreational cannabis in Canada, Kal Malhi, President of Cannabix states, “We welcome the recommendations from the Task Force members which speaks to the urgent need to identify and approve a scientific tool to collect court approved evidence of marijuana impaired driving. Cannabix is developing its Cannabix Marijuana Breathalyzer to help law enforcement and employers to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in various jurisdictions.  The report confirms that marijuana impaired driving poses an increasing risk to the public and law enforcement needs a tool that can be used at the roadside to collect court admissible evidence of impairment at the time of the test. The report is concrete validation of the work we have been doing at Cannabix in developing our Cannabix Marijuana Breathalyzer and being a leader and early mover in this space.”  
The Task Force agrees with experts in law enforcement that impaired driving is a serious issue that exists currently and requires immediate action to protect public safety.  The report also confirms that the level of THC in bodily fluids cannot be used to reliably indicate the degree of impairment or crash risk. In addition, the Company notes and applauds the following specific recommendations to provincial Ministers across Canada, which include:​

  • Determining whether to establish a per se limit as part of a comprehensive approach to cannabis-impaired driving and re-examine per se limits should a reliable correlation between THC levels and impairment be established;
  • Supporting the development of an appropriate roadside drug screening device for detecting THC levels, and invest in these tools; 
  • Investing in baseline data collection and ongoing surveillance and evaluation in collaboration with provinces and territories.

Cannabix Technologies is working to develop a rigorous trial with expedited ethics approval to begin detailed scientific trial testing of the Cannabix Marijuana Breathalyzer. This trial is intended to compare the Cannabix Marijuana Breathalyzer utilizing breath samples with correlated blood samples. The Company plans to use key metrics and guidance from Drugs and Driving Committee (DDC), which is an advisory body to the Canadian Department of Justice on issues relating to drug-impaired driving and has been given a mandate to develop reports regarding drugs that are proposed for zero-tolerance and per se legislation, including cannabis/THC.

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.